Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 2/20 | 0.73 |
| ▸ | TP53 | P04637 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31065609 | 1.00 | STING1 (0.73) | STING1TP53MAPTSMN1; SMN2MEN1 | |
| SCHEMBL21932350 | 1.00 | STING1 (0.73) | STING1TP53MAPTSMN1; SMN2MEN1 | |
| SCHEMBL31065616 | 1.00 | STING1 (0.73) | STING1TP53MAPTSMN1; SMN2MEN1 | |
| SCHEMBL21932216 | 1.00 | STING1 (0.73) | STING1TP53MAPTSMN1; SMN2MEN1 | |
| SCHEMBL31065580 | 0.91 | STING1 (0.71) | STING1TP53MAPTSMN1; SMN2MEN1 | |
| SCHEMBL21932446 | 0.89 | STING1 (0.72) | STING1TP53MAPTSMN1; SMN2MEN1 | |
| SCHEMBL31065605 | 0.89 | STING1 (0.72) | STING1TP53MAPTSMN1; SMN2MEN1 | |
| SCHEMBL22000894 | 0.89 | STING1 (0.72) | STING1TP53MAPTSMN1; SMN2MEN1 | |
| SCHEMBL21932342 | 0.89 | STING1 (0.72) | STING1TP53MAPTSMN1; SMN2MEN1 | |
| SCHEMBL21932273 | 0.84 | STING1 (0.84) | STING1TP53MAPTSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11571423-B2 | Small molecule modulators of human sting | CURADEV PHARMA LIMITED (GB) | 2023-02-07 | — | — | US | disclosed |
| EP-3642198-B1 | SMALL MOLECULE MODULATORS OF HUMAN STING | CURADEV PHARMA LTD (GB) | 2022-03-16 | — | — | EP | disclosed |
| US-20200147083-A1 | SMALL MOLECULE MODULATORS OF HUMAN STING | CURADEV PHARMA LIMITED (GB) | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11571423-B2 | Small molecule modulators of human sting | STING1, IRF3, CGAS | STING1 1/4885TP53 196/4885MAPT 4702/4885 |
| US-20200147083-A1 | SMALL MOLECULE MODULATORS OF HUMAN STING | STING1, IRF3, CGAS | STING1 1/4885TP53 196/4885MAPT 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.